Advisors Asset Management Inc. Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

Advisors Asset Management Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 170,257 shares of the biopharmaceutical company’s stock after selling 35,774 shares during the period. Advisors Asset Management Inc.’s holdings in Gilead Sciences were worth $18,899,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC boosted its position in Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank purchased a new position in shares of Gilead Sciences in the second quarter worth about $2,150,268,000. Invesco Ltd. raised its position in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Finally, Amundi lifted its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent research reports. Leerink Partners lifted their price objective on shares of Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Truist Financial raised their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, BMO Capital Markets upped their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.73.

Gilead Sciences Stock Performance

Shares of GILD opened at $147.23 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $153.13. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a market cap of $182.67 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36. The stock has a 50-day moving average price of $128.39 and a 200-day moving average price of $121.53.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period last year, the firm posted $1.90 earnings per share. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 319,391 shares of company stock worth $44,141,101 in the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat estimates: Gilead reported $1.86 EPS vs. a $1.83 consensus and revenue rose ~4.7% YoY, helping demonstrate underlying portfolio resilience. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Dividend bump: Board raised the quarterly dividend by 3.8% to $0.82, supporting the stock’s income profile for yield‑focused investors. Gilead Sciences Announces 3.8% Dividend Increase
• Positive Sentiment: Pipeline and product momentum: Management cited growth in liver‑disease and HIV franchises and potential launches (including additional HIV options and two cancer therapy filings/approvals) and analysts remain upbeat on launches like Yeztugo. These could underpin medium‑term growth. WSJ: Gilead Profit Rises on Liver Disease, HIV Products Seeking Alpha: Q4 Preview
• Neutral Sentiment: Official earnings release and slide deck available for review — useful for digging into product-level trends and guidance assumptions. MarketWatch: Q4 and Full-Year Results
• Neutral Sentiment: Reported short‑interest data in filings is effectively meaningless/garbled for the period cited (shows 0 shares), so it provides no clear near‑term pressure signal.
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–$8.85 sits at the low end of Street forecasts and revenue guidance ($29.6–$30.0B) came in below consensus — the primary driver of the stock’s pullback as investors re‑price growth expectations. Benzinga: Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
• Negative Sentiment: Analyst/headline pushback: Several outlets flagged that the light outlook could weigh on the stock despite a clean beat, amplifying downward pressure in the session. Investor’s Business Daily: Light Outlook May Hurt Stock Reuters: Beat but Light Forecast
• Negative Sentiment: Insider selling: CEO disclosed a roughly $17.3M stock sale recently, which some investors view negatively even if driven by personal liquidity. AmericanBankingNews: CEO Stock Sale

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.